1Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev,2004,17(4) :697-728.
2Chaudhry R, Varshney AK, Malhotra P. Adhesion proteins of Mycoplasma pneumoniae. Front Biosci, 2007,12: 690-699.
3Dumke R, Catrein I, Pirkil E, et al. Subtyping of Mycoplasma pneumoniae isolates based on extended genome sequencing and on expression profiles. Int J Med Microbiol,2003,292(7-8) :513-525.
4Yavlovich A, Tarshis M, Rottem S. Intermalization and intracellular survival of Mycoplasma pneumoniae by non-phagocytic cells. FEMS Microbiol Lett, 2004,233(2) :241-246.
5Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci USA ,2006,103 (17) : 6724-6729.
6Kannan TR,Provenzano D,Wright JR,et al.Identification and characterization of human surfactant protein A binding protein of Myeoplasma pneumoniae. Infect Immun,2005,73(5) :2828-2834.
7Shimizu T, Kida Y,Kuwano K. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6. J Immunol,2005,175(7) :4641-4646.
8Into T, Nodasaka Y, Hasebe A, et al. Mycoplasmal lipoproteins induce toll-like receptor 2- and caspases-mediated cell death in lymphocytes and monocytes. Microbiol Immunol,2002,46(4) :265-276.
9Into T, Kiura K, Yasuda M, et al. Stimulation of human Toll-like receptor (TLR) 2 and TLR6 with membrane lipoproteins of Mycoplasma fermentans induces apoptotic cell death after NF-kappa B activation. Cell Microbiol, 2004,6(2) : 187-199.
10Stelmach I, Podsiadlowicz-Borzecka M, Grzelewski T,et al. Humoral and cellular immunity in children with Mycoplasma pneumoniae infection: a 1- year prospective study. Clin Diagn Lab Immunol, 2005, 12 (10) : 1246- 1250.
